Kyverna Therapeutics Income Statement (2023-2026) | KYTX

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter) 8.71M10.40M13.64M17.16M22.48M27.32M29.19M33.48M37.43M35.82M30.46M30.01M30.07M
Selling, General & Administrative (Quarter) 2.73M2.90M2.64M4.21M6.88M6.11M9.58M7.56M9.97M8.59M8.27M9.27M11.29M
Operating Expenses (Quarter) 11.45M13.30M16.28M21.38M29.36M33.44M38.77M41.04M47.41M44.41M38.73M39.28M41.37M
Operating Income (Quarter) -11.45M-13.30M-16.28M-21.38M-29.36M-33.44M-38.77M-41.04M-47.41M-44.41M-38.73M-39.28M-41.37M
EBIT (Quarter) -11.45M-13.30M-16.28M-21.38M-29.36M-33.44M-38.77M-41.04M-47.41M-44.41M-38.73M-39.28M-41.37M
Non-operating items
Interest & Investment Income (Quarter) 0.35M0.26M0.88M0.79M2.73M4.69M4.36M3.58M2.83M2.36M2.00M1.91M2.33M
Other Non Operating Income (Quarter) -0.00M-0.01M-0.01M-0.03M-0.03M-0.02M-0.04M0.00M-0.03M-0.02M-0.05M0.02M-0.02M
Non Operating Income (Quarter) -0.00M-0.01M-0.01M-1.39M2.67M-0.02M4.28M-11.66M2.77M-0.02M-0.05M0.02M-0.02M
Net income details
EBT (Quarter) -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M
Profit After Tax (Quarter) -11.14M-13.09M-15.46M-20.70M-26.69M-28.80M-34.49M-37.49M-44.60M-42.08M-36.79M-37.80M-39.70M
Income from Continuing Operations (Quarter) -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M
Consolidated Net Income (Quarter) -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M
Income towards Parent Company (Quarter) -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M
Net Income towards Common Stockholders (Quarter) -11.14M-13.08M-15.45M-20.64M-26.67M-28.78M-34.45M-37.49M-44.61M-42.06M-36.73M-37.82M-39.71M
Additional items
EPS (Basic) (Quarter) -12.10-20.86-23.27-26.86-1.12-0.67-0.80-0.88-1.03-0.97-0.85-0.79-0.66
EPS (Weighted Average and Diluted) (Quarter) -12.10-20.86-23.27-26.86-1.12-0.67-0.80-0.88-1.03-0.97-0.85-0.79-0.66
Shares Outstanding (Weighted Average) (Quarter) 0.92M0.60M0.63M0.67M23.75M43.13M43.16M38.33M43.22M43.23M43.28M44.26M60.43M
Shares Outstanding (Diluted Average) (Quarter) 0.92M0.63M0.63M0.67M23.75M33.44M43.16M38.33M43.22M43.22M43.42M44.26M60.43M
EBITDA (Quarter) -11.12M-13.08M-15.46M-21.38M-26.70M-28.84M-34.30M-41.04M-44.74M-42.10M-36.74M-39.28M-39.92M
Interest Expenses (Quarter) 0.04M0.05M0.05M0.05M0.04M0.04M0.03M0.03M0.03M0.01M0.01M0.44M0.67M